The Claim
The monoclonal autoantibody M22TM, derived from a Graves’ disease patient, binds the TSH receptor with high affinity and has been used to develop highly sensitive and automated diagnostic assays for thyroid-stimulating autoantibodies that are now used globally.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A laboratory-made antibody called M22TM, originally isolated from a person with Graves’ disease, binds tightly to the TSH receptor and is used in diagnostic tests worldwide to detect thyroid-stimulating autoantibodies.
See the scientific wording
The monoclonal autoantibody M22TM, derived from a Graves’ disease patient, binds the TSH receptor with high affinity and has been used to develop highly sensitive and automated diagnostic assays for thyroid-stimulating autoantibodies that are now used globally.
A lab-made antibody that mimics the harmful antibodies in Graves' disease sticks tightly to the thyroid hormone receptor in a specific way that keeps it turned on. This same antibody is used in blood tests to find other similar antibodies in patients, because it binds exactly like them and lets machines detect even tiny amounts.
What the research says
1 studyScientists made a lab-grown antibody called M22TM from a Graves’ disease patient, and it sticks tightly to the thyroid hormone receptor. This antibody is now used in blood tests around the world to detect the harmful antibodies that cause Graves’ disease.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.